Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning ...
Novo Nordisk shares jump after Wegovy price cuts announced
Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...
Fierce Biotech4d
Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
STAT8d
Novo Nordisk to sell obesity drug Wegovy direct to patients at lower price
Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Novo Nordisk Shares Climb as Wegovy Price Slashed Over 50%
Novo Nordisk (NVO, Financial) shares rallied 4% Wednesday morning after the drug maker cut the price of its popular ...